SBIR-STTR Award

Rapid at-home Detection for Serologic Status of Hepatitis C Virus (HCV) Infection
Award last edited on: 4/26/2023

Sponsored Program
SBIR
Awarding Agency
NIH : NCI
Total Award Amount
$400,000
Award Phase
1
Solicitation Topic Code
441
Principal Investigator
Hong Qi

Company Information

Qoolabs Inc

4186 Sorrento Valley Boulevard Suite D
San Diego, CA 92121
   (858) 348-0988
   info@qoolabs.com
   www.qoolabs.com
Location: Single
Congr. District: 51
County: San Diego

Phase I

Contract Number: 75N91022C00028
Start Date: 9/19/2022    Completed: 9/18/2023
Phase I year
2022
Phase I Amount
$400,000
Hepatitis C Virus (HCV) infection is a worldwide health concern, affecting about 3% of the world’s population. Over 2 million people in the United States have a current HCV infection, however, nearly half of them are not aware of their infection. HCV-related end stage liver disease is the leading reason for liver transplantation in the USA. Because symptoms are generally absent in individuals with chronic HCV infection, appropriate HCV testing must be linked with risk factors to allow for recognition of infection. Effective treatments for HCV infection are currently available. However, diagnosis is a bottleneck for appropriate HCV care and treatment, especially in low- and medium-income countries. In this project, Qoolabs proposes to develop at-home rapid test for HCV antibody detection The test will use finger prick blood samples, can be completed within 20 minutes without special instrument. The HCV antibody at-home test will be complementary with the HCV core antigen rapid tests that are being developed. With both core antigen and total antibody detection, it is feasible to achieve accurate and cost-effective at-home serodiagnostics to fulfill the need of screening large populations.

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----